Ortiz MJ

Language: Spanish
References: 3
Page: 87-88
PDF size: 88.46 Kb.

REFERENCES

1. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018; 391 (10127): 1263-1273.

2. Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology. 2021; 96 (3): e376-e386.

3. European Medicines Agency. Summary of product characteristics. 2020 [Accessed 23 May 2020]. Available in: https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf